NEW YORK, July 8 (Reuters) - An experimental anti-clotting medicine from Bristol-Myers Squibb Co. (BMY.N: Quote, Profile, Research) and Pfizer Inc. met its main effectiveness and safety goals in a mid-stage study, researchers said on Sunday, positioning it as a future option over current popular but problematic drugs.
